After 2 years of shortages, the compounding market for glucagon-like peptide 1 (GLP-1) medications has exploded to include telehealth companies and compounding pharmacies, whose products are not reviewed by the US Food and Drug Administration (FDA) for safety, effectiveness, or quality....
In typical situations, compounding pharmacies provide personalized formulations of FDA-approved drugs, for instance, if a patient is allergic to a specific ingredient, requires a special dosage, or needs a liquid version of a drug instead of a pill form. But, when commercially available drugs ar...
The FDA allows and even encourages compounding pharmacies to produce and sell copycats when a drug is in short supply, and the wildly popular GLP-1 drugs have enduring shortages — first reported in March 2022 for semaglutide and in December 2022 for tirzepatide. The drugs have regi...
The copycat drugs are made by specialized pharmacies known as compounding pharmacies, which are allowed by the U.S. Food and Drug Administration to make off-label versions of pharmaceutical products that are in short supply, she says. But recently the FDA has warned that some compounding pharmac...
Consumers should be wary of online purchases of EpiPen over the Internet, even those that claim to be Canadian pharmacies. The product might be contaminated or a fraud containing no medication at all. It’s not worth it to purchase a life-saving drug when you can’t be sure of it’s ...
"the fda is concerned that claims made by [compounding pharmacies] about so-called bio-identical hormones can mislead practitioners and consumers about the risks and benefits of these drugs," said deborah m. autor, esq, director of the office of compliance at the fda's center for drug ...
Oops. I meant an FDA-approved drug for amyotrophic lateral sclerosis (ALS), NOT Alzheimer’s disease (although riluzole isunder study for Alzheimer’s). Brain fart. Oh, well. In any event, come back to me when you have some compelling preclinical data and/or early phase clinica...
American Pharmacies: Powering the Profession Through Leadership Brian Nowosielski December 3rd 2024 Podcast Drug Topics sat down with Laird Leavoy, President of American Pharmacies, to discuss the role leadership plays in the independent pharmacy industry....
The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment. American Pharmacies: Powering the Profession Through Leadership Brian Nowosielski December 3rd 2024 Podcast Drug Topics sat down with Laird Leavoy, Presiden...
The new medications show promise for inducing weight loss, but many aren't FDA-approved for that use.